Albuminuria Clinical Trials

7 recruiting

Albuminuria Trials at a Glance

9 actively recruiting trials for albuminuria are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 4 with 3 trials, with the heaviest enrollment activity in Aguascalientes, Aurora, and Bagamoyo. Lead sponsors running albuminuria studies include Centenario Hospital Miguel Hidalgo, Consorzio Mario Negri Sud, and Ace Cells Lab Limited.

Browse albuminuria trials by phase

Treatments under study

About Albuminuria Clinical Trials

Looking for clinical trials for Albuminuria? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Albuminuria trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Albuminuria clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

ObesityCardiovascular DiseasesChronic Kidney Diseases+8 more
Swiss Tropical & Public Health Institute1,200 enrolled1 locationNCT05881447
Recruiting
Phase 4

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

AdolescentAlbuminuriaChronic Kidney Disease (Mild to Moderate)
Centenario Hospital Miguel Hidalgo200 enrolled1 locationNCT07405216
Recruiting

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Diabetes MellitusAlbuminuriaDiabetic Kidney Disease+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)100,000 enrolled1 locationNCT00342927
Recruiting

Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

Chronic Kidney DiseasesMolecular Sequence VariationAlbuminuria+4 more
Herlev Hospital300 enrolled13 locationsNCT04916132
Recruiting

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

Autonomic DysfunctionHypertensionBlood Pressure Disorders+15 more
Wake Forest University Health Sciences125 enrolled1 locationNCT04752293
Recruiting
Phase 4

ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

Chronic Kidney DiseaseDiabetic NephropathiesChronic Kidney Disease (Stages 4 and 5)+5 more
Ace Cells Lab Limited300 enrolled1 locationNCT07187713
Recruiting
Not Applicable

Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome

Diabetes MellitusStrokeChronic Kidney Disease(CKD)+4 more
Universidade do Porto150 enrolled1 locationNCT07173062
Recruiting
Phase 4

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

Albuminuria
University of Colorado, Denver50 enrolled1 locationNCT05498116
Recruiting
Phase 3

Long term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.

Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
Consorzio Mario Negri Sud2,100 enrolled1 locationACTRN12607000333415